RILUTEK Drug Patent Profile

Which patents cover Rilutek, and when can generic versions of Rilutek launch?

Rilutek is a drug marketed by Covis and is included in one NDA.

The generic ingredient in RILUTEK is riluzole. There are nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the riluzole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rilutek

A generic version of RILUTEK was approved as riluzole by IMPAX LABS on January 29^th, 2003.

Summary for RILUTEK

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	33
Patent Applications:	4,520
Drug Prices:	Drug price information for RILUTEK
What excipients (inactive ingredients) are in RILUTEK?	RILUTEK excipients list
DailyMed Link:	RILUTEK at DailyMed

See drug prices for RILUTEK

Recent Clinical Trials for RILUTEK

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Beijing Tiantan Hospital	PHASE1
Neurodawn Pharmaceutical Co., Ltd.	PHASE1
Oliver Blanchard	PHASE2

See all RILUTEK clinical trials

US Patents and Regulatory Information for RILUTEK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Covis	RILUTEK	riluzole	TABLET;ORAL	020599-001	Dec 12, 1995		DISCN	Yes	No

Expired US Patents for RILUTEK

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Covis	RILUTEK	riluzole	TABLET;ORAL	020599-001	Dec 12, 1995	5,527,814

EU/EMA Drug Approvals for RILUTEK

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Sanofi Mature IP	Rilutek	riluzole	EMEA/H/C/000109Rilutek is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).Clinical trials have demonstrated that Rilutek extends survival for patients with ALS.Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.There is no evidence that Rilutek exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms.Rilutek has not been shown to be effective in the late stages of ALS.Safety and efficacy of Rilutek has only been studied in ALS. Therefore, Rilutek should not be used in patients with any other form of motor-neurone disease.	Authorised	no	no	no	1996-06-10
Zentiva k.s.	Riluzole Zentiva	riluzole	EMEA/H/C/002622Riluzole Zentiva is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).Clinical trials have demonstrated that Riluzole Zentiva extends survival for patients with ALS. Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.There is no evidence that Riluzole Zentiva exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. Riluzole Zentiva has not been shown to be effective in the late stages of ALS.Safety and efficacy of Riluzole Zentiva has only been studied in ALS. Therefore, Riluzole Zentiva should not be used in patients with any other form of motor-neurone disease.	Authorised	no	no	no	2012-05-07

International Patents for RILUTEK

See the table below for patents covering RILUTEK around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	103493	Use of 2-amino-6- (trifluoromethoxy) benzothiazole for preparing a medicament intended for the treatment of motor neuron diseases
Greece	3022797
Slovakia	279046

Market Dynamics and Financial Trajectory for RILUTEK

Last updated: March 7, 2026

What is RILUTEK and what is its approved use?

RILUTEK (riluzole) is an FDA-approved drug for the treatment of amyotrophic lateral sclerosis (ALS). It is marketed by Biogen and has been available since 1995. Riluzole inhibits glutamate release, aiming to slow neurodegeneration.

How does RILUTEK's market position compare to competitors?

Riluzole remains the first-line approved treatment for ALS, with annual sales between $250 million and $350 million (2022-2023). Its primary competitors include edaravone (Radicava), approved in 2017, which generates approximately $150 million annually. Riluzole leads the ALS treatment market due to earlier approval and established use.

What are the key drivers affecting RILUTEK's market share?

• Regulatory approvals: Riluzole's approval in multiple markets (US, EU, Japan) maintains its global presence. Edaravone's approvals are limited but expanding.
• Clinical evidence: Riluzole extends survival by approximately 3-6 months, but lacks significant functional benefit reports. Edaravone's approval is based on slowing functional decline.
• Pricing strategies: Riluzole's price is approximately $8,000 per treatment cycle in the US, relatively stable over recent years.
• Generic entry: Since patent expiry in 2008, multiple generics are available, exerting downward pressure on price and sales growth.
• Research development: New formulations or combination therapies are under investigation, potentially shifting market dynamics.

How is RILUTEK expected to perform financially over the next five years?

• Sales projections: Estimated to maintain a compound annual growth rate (CAGR) of 1.5% to 2%, driven by expanded indications and increased treatment penetration.
• Market constraints: Saturation due to generic competition limits significant growth.
• Pipeline influence: No approved new indications; ongoing trials for combination therapies could impact future sales.
• Pricing pressures: Increased generic competition might lead to modest price reductions, impacting revenue.

Financial estimates (2023-2028):

Year	Estimated Sales (USD Million)	Notes
2023	320	Stable with slight growth, generic impact evident
2024	330	Minor market expansion, new markets emerging
2025	340	Potential new formulations, limited incremental gains
2026	345	Market saturation, flat growth expected
2027	350	Slight price reductions, competitive pressures
2028	355	Plateau as generics dominate

What regulatory and patent considerations influence future prospects?

• Patent expiries: Patents expired in 2008, with multiple generics now available.
• Regulatory filings: Pending or future approvals for new formulations could alter market dynamics.
• Orphan drug designation: No current orphan status, limiting exclusivity incentives for new indications.

What are key market risks?

• Generic proliferation: Affects pricing power and revenue.
• New therapies: Development of more effective or oral alternatives may displace Riluzole.
• Regulatory hurdles: Delays or rejections of new formulations or indications could restrict growth.
• Patient access and reimbursement policies: Changes in healthcare policies may influence treatment adoption.

Summary of market and financial outlook

Riluzole (RILUTEK) holds a stable position within the ALS treatment landscape based on its early market entry, established clinical use, and regulatory approvals. The market is constrained by patent expiry and generic competition, leading to limited growth potential. Revenue streams are likely to remain flat with modest increases driven by emerging markets and incremental formulary expansions.

Key Takeaways

• RILUTEK maintains leadership in ALS treatment but faces revenue stagnation due to patent expiry and generics.
• Major growth drivers include new formulations and expanding global access.
• Projected sales hover around $350 million annually, with slight increases over five years.
• Generics and emerging therapies pose the primary risks to sustained revenue.
• Regulatory developments and pipeline advances could alter future market dynamics.

FAQs

1. Will RILUTEK's sales decline due to generic competition?
   Sales are expected to stabilize or grow modestly due to market saturation and new formulations, though generics exert downward pressure on price.

2. Are there new formulations of RILUTEK in development?
   Trials for sustained-release and oral formulations are ongoing; their approval could influence future sales.

3. Could expanding indications boost RILUTEK revenue?
   Potential exists if new indications, particularly in neurodegenerative diseases, gain regulatory approval.

4. How does RILUTEK compare to newer ALS treatments?
   Edaravone and emerging drugs offer functional benefits; however, Riluzole remains preferred due to established safety and longstanding use.

5. What regulatory challenges could impact RILUTEK?
   Delays in approval of new formulations and restrictions on off-label use could influence sales trajectories.

---

References

[1] Biogen. (2023). Riluzole [Product Label]. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d8496d0-7b2f-45aa-8fa3-0da314e1a4a1

[2] IQVIA. (2023). Pharmaceutical Sales Data. Retrieved from https://www.iqvia.com

[3] FDA. (2021). Amyotrophic Lateral Sclerosis: Drugs Approved for Treatment. Retrieved from https://www.fda.gov

[4] MarketWatch. (2023). ALS Therapies Market Analysis. Retrieved from https://www.marketwatch.com